Proactive Research analyst Daniel Appiah presents his research on Oxford Cannabinoid Technologies (OCT) which is a UK-based pharmaceutical company developing next-generation, non-addictive pain medications to replace opioids.
Management estimated that the market will grow to £42.5bln by 2027 and OCT aims to gain an aggressive share of this market.
OCT's candidates target the body's endocannabinoid system. OCT has a cost effective development plan using blue-chip partners that could enable its products to receive regulatory approvals from 2027 onwards.